Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -665.00K | 416.00K | -1.02M | 88.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -665.00K | 416.00K | -1.02M | 88.64M |
| Cost of Revenue | 22.12M | -13.31M | 58.25M | 30.77M | 153.01M |
| Gross Profit | -22.12M | 12.65M | -57.83M | -31.79M | -64.37M |
| SG&A Expenses | 15.68M | 17.10M | 17.83M | 21.65M | 57.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | 22.85M | -- |
| Total Operating Expenses | 37.80M | 39.99M | 76.08M | 75.26M | 210.77M |
| Operating Income | -37.80M | -40.65M | -75.66M | -76.29M | -122.13M |
| Income Before Tax | -35.91M | -38.18M | -72.70M | -72.70M | -118.55M |
| Income Tax Expenses | -- | -635.00K | -- | -- | 242.00K |
| Earnings from Continuing Operations | -35.91M | -37.55M | -72.70M | -72.70M | -118.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.91M | -37.55M | -72.70M | -72.70M | -118.79M |
| EBIT | -37.80M | -40.65M | -75.66M | -76.29M | -122.13M |
| EBITDA | -37.65M | -40.49M | -75.44M | -76.08M | -121.82M |
| EPS Basic | -0.42 | -0.55 | -1.07 | -1.07 | -1.75 |
| Normalized Basic EPS | -0.26 | -0.44 | -0.67 | -0.67 | -1.09 |
| EPS Diluted | -0.42 | -0.55 | -1.07 | -1.07 | -1.75 |
| Normalized Diluted EPS | -0.26 | -0.44 | -0.67 | -0.67 | -1.09 |
| Average Basic Shares Outstanding | 85.70M | 68.59M | 68.09M | 68.02M | 67.85M |
| Average Diluted Shares Outstanding | 85.70M | 68.59M | 68.09M | 68.02M | 67.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |